ApoA-II maintains HDL levels in part by inhibition of hepatic lipase: Studies in apoA-II and hepatic lipase double knockout mice

Journal of Lipid Research

Volumn 40, Issue 6, 1999, Pages 1064-1070

  Weng, Wei ^a,b,d   Brandenburg, Neal A ^a,b,d   Zhong, Shaobin ^b,c,d   Halkias, Joanna ^a,b,d   Wu, Lin ^a,b,d   Jiang, Xian Cheng ^b,c,d   Tall, Alan ^b,c,d   Breslow, Jan L ^a,b,d  

^a Lab of Biochem Genet and Metab   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c Division of Molecular Genetics   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

apoA I; apoA II; HDL cholesterol; Hepatic lipase

Indexed keywords

APOLIPOPROTEIN A2; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER TRIACYLGLYCEROL LIPASE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATABOLISM; CHOLESTEROL BLOOD LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; HYPOTHESIS; ISCHEMIC HEART DISEASE; KNOCKOUT MOUSE; LIPOLYSIS; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEIN A-II; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; CROSSES, GENETIC; FEMALE; HUMANS; HYDROLYSIS; LIPASE; LIPOLYSIS; LIPOPROTEINS, HDL; LIVER; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PARTICLE SIZE; TRIGLYCERIDES;

EID: 0033058360     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Miller, N. E. 1987. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am. Heart J. 113: 589-597.
2. Castelli, W. P., R. J. Garrison, P. W. F. Wilson, R. D. Abbott, S. Kalousdian, and W. B. Kannel. 1986. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. J. Am. Med. Assoc. 256: 2835-2838.
3. Gordon, T., W. P. Castelli, M. C. Hjortland, W. B. Kannel, and T. R. Dawber. 1977. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62: 707-714.
4. Gordon, D. J., J. L. Probstfield, R. J. Garrison, J. D. Neaton, W. P. Castelli, J. D. Knoke, D. R. Jacobs, Jr., S. Bangdiwala, and H. A. Tyroler. 1989. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79: 8-15.
5. Eisenberg, S. 1984. High density lipoprotein metabolism. J. Lipid Res. 25: 1017-1058.
6. Tall, A. R. 1990. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J. Clin. Invest. 86: 379-384.
7. Breslow, J. L. 1995. Disorders of HDL metabolism. In The Metabolic Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 2031-2052.
8. Brinton, E. A., S. Eisenberg, and J. L. Breslow. 1994. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler. Thromb. 14: 707-720.
9. Weng, W., and J. L. Breslow. 1996. Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. Proc. Natl. Acad. Sci. USA. 93: 14788-14794.
10. Zhong, S. B., I. J. Goldberg, C. Bruce, E. M. Rubin, J. L. Breslow, and A. R. Tall. 1994. Human apoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice. J. Clin. Invest. 94: 2457-2467.
11. Homanics, G. E., H. V. de Silva, J. Osada, S. H. Zhang, H. Wong, J. Borensztajn, and N. Maeda. 1995. Mild dyslipidemia in mice following targeted inactivation of the hepatic lipase gene. J. Biol. Chem. 270: 2974-2980.
12. 131I-labeled plasma proteins. Phys. Med. Biol. 2: 36-53.
13. Baginsky, M. L., and M. V. Brown. 1979. A new method for the measurement of lipoprotein lipase in postheparin plasma using sodium dodecyl sulfate for the inactivation of hepatic triglyceride lipase. J. Lipid Res. 20: 548-556.
14. Kuusi, T., P. Saarinen, and E. A. Nikkila. 1980. Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein2 in man. Atherosclerosis. 36: 589-593.
15. Applebaum-Bowden, D., S. M. Haffner, P. W. Wahl, J. J. Hoover, G. R. Warnick, J. J. Albers, and W. R. Hazzard. 1985. Postheparin plasma triglyceride lipases. Relationships with very low density lipoprotein triglyceride and high density lipoprotein2 cholesterol. Arteriosclerosis. 5: 273-282.
16. Jackson, R. L., M. T. Yates, C. A. McNerney, and M. L. Kashyap. 1990. Relationship between post-heparin plasma lipases, triglycerides and high density lipoproteins in normal subjects. Horm. Metab. Res. 22: 289-294.
17. Blades, B., G. L. Vega, and S. M. Grundy. 1993. Activities of lipoprotein lipase and hepatic triglyceride lipase in postheparin plasma of patients with low concentrations of HDL cholesterol. Arterioscler. Thromb. 13: 1227-1235.
18. Guerra, R., J. Wang, S. M. Grundy, and J. C. Cohen. 1997. A hepatic lipase (LIPG) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc. Natl. Acad. Sci. USA. 94: 4532-4537.
19. Busch, S. J., R. L. Barnhart, G. A. Martin, M. C. Fitzgerald, M. T. Yates, S. J. T. Mao, C. E. Thomas, and R. L. Jackson. 1994. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J. Biol. Chem. 269: 16376-16382.
20. Fan, J., J. Wang, A. Bensadoun, S. J. Lauer, Q. Dang, R. W. Mahley, and J. M. Taylor. 1994. Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proc. Natl. Acad. Sci. USA. 91: 8724-8728.
21. Breckenridge, W. C., J. A. Little, P. Alaupovic, C. S. Wang, A. Kuksis, G. Kakis, F. Lindgren, and G. Gardiner. 1982. Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis. 45: 161-179.
22. Carlson, L. A., L. Homnquist, and P. Nilsson-Ehle. 1986. Deficiency of hepatic lipase activity in post-heparin plasma in familial hyper-alpha-triglyceridemia. Acta Med. Scand. 219: 435-447.
23. Hegele, R. A., J. A. Little, C. Vezina, G. F. Maguire, L. Tu, T. S. Wolever, D. J. A. Jenkins, and P. W. Connelly. 1993. Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics. Arterioscler. Thromb. 13: 720-728.
24. Thuren, T., R. W. Wilcox, P. Sisson, and M. Waite. 1991. Hepatic lipase hydrolysis of lipid monolayers. Regulation by apolipoproteins. J. Biol. Chem. 266: 4853-4861.
25. Hime, N., P. Barter, and K. Rye. 1998. The influence of apolipoproteins on the hepatic lipase-mediated hydrolysis of high density lipoprotein phospholipid and triacylglycerol. J. Biol. Chem. 273: 27191-27198.
26. Jahn, C. E., J. C. Osborne, E. J. Schaffer, and H. B. Brewer. 1983. Activation of the enzymic activity of hepatic lipase by apolipoprotein A-II. Characterization of a major component of high density lipoprotein as the activating plasma component in vitro. Eur. J. Biochem. 131: 25-29.
27. Shirai, K., R. L. Barnhart, and R. L. Jackson. 1981. Hydrolysis of human plasma high density lipoprotein 2-phospholipids and triglycerides by hepatic lipase. Biochem. Biophys. Res. Commun. 100: 591-599.
28. Mowri, H-O., J. R. Patsch, A. M. Gotto, Jr., and W. Patsch. 1996. Apolipoprotein A-II influences the substrate properties of human HDL2 and HDL3 for hepatic lipase. Arterioscler. Thromb. Vasc. Biol. 16: 755-762.
29. Mowri, H-O., W. Patsch, L. D. Smith, A. M. Gotto, Jr., and J. R. Patsch. 1992. Different reactivities of high density lipoprotein2 subfractions with hepatic lipase. J. Lipid Res. 33: 1269-1279.
30. Tikkanen, M. J., E. A. Nikkila, T. Kuusi, and S. Sipinen. 1981. Different effects of two progestins on plasma high density lipoprotein (HDL2) and postheparin plasma hepatic lipase activity. Atherosclerosis. 40: 365-369.
31. Moorjani, S., A. Dupont, F. Labrie, P. J. Lupien, C. Gagne, D. Brun, M. Giguere, A. Belanger, and L. Cusan. 1988. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide. J. Clin. Endocrinol. Metab. 66: 314-322.
32. Brinton, E. A. 1996. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate. Arterioscler. Thromb. Vasc. Biol. 16: 431-440.
33. Glad, B. W., D. E. Wilson, D. B. Cook, P. K. Working, and M. E. Adler. 1978. Heparin resistance and decreased hepatic triglyceride hydrolase release during long-term estrogen-progestin treatment. Metabolism. 27: 53-60.
34. Staels, B., H. Jansen, A. van Tol, G. Stahnke, H. Will, G. Verhoeven, and J. Auwerx. 1990. Development, food intake, and ethinylestradiol influence hepatic triglyceride lipase and LDL-receptor mRNA levels in rats. J. Lipid Res. 31: 1211-1218.
35. Srivastava, R. A. K., R. T. Kitchens, and G. Schonfeld. 1994. Regulation of the apolipoprotein AIV gene expression by estrogen differs in rat and mouse. Eur. J. Biochem. 222: 507-514.